Working… Menu

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (MOONSTONE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03955471
Recruitment Status : Suspended (This study has temporarily held recruitment activities to perform a pre-planned interim analysis. Other elements of this study are still ongoing.)
First Posted : May 20, 2019
Last Update Posted : October 9, 2020
Gynecologic Oncology Group
Information provided by (Responsible Party):
Tesaro, Inc.

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : May 18, 2022
Estimated Study Completion Date : October 30, 2024